. At the end of follow-up, 55% of the total cohort were off medication and in remission. Approximately 70% of those stopping medication remained seizure free. At the time of diagnosis, the best predictors of remission, determined by a multivariate analysis scoring system, were 1) age <12 years at onset, 2) normal intelligence, 3) no prior neonatal seizures, and 4) fewer than 21 seizures before treatment. Prediction was improved after 12 months follow-up, when a score for the seizure frequency between 6 and 12 months was included. Patients with absence and minor motor seizures were excluded from the study. Seizure type and the EEG were not of predictive value. (Camfield C, Camfield P et al. Outcome of childhood epilepsy: A population-based study with a simple predictive scoring system for those treated with medication.
excluded from the study. Seizure type and the EEG were not of predictive value. (Camfield C, Camfield P et al. Outcome of childhood epilepsy: A population-based study with a simple predictive scoring system for those treated with medication. 1 Pediatr Tune 1993; 122: 861-868). ( Reprints: Carol Camfield MD, IWK Children's Hospital, Box 3070, Halifax, Nova Scotia B3H 3G9, Canada).
COMMENT. During the study period, 1977-1985 , the number of seizurefree years required before mediction withdrawal was attempted changed from 4 to 2 years. The authors endorse the stopping of medica¬ tion after 2 seizure-free years, regardless of the predicted prognosis.
A social outcome of epilepsy study in 337 intellectually normal children included in this Nova Scotia population found school failure in 34%, mental health consultation in 22%, psychotropic medication used in 5%, unemployment 20%, and criminal conviction in 2%. Learning disorders and more than 21 seizures before treatment for epilepsy were predictive of an unfavorable social outcome, but seizure control and EEG were non-predictive. (Camfield C, Camfield P et al. T Pediatr Tune 1993; 122: 869-873) .
CARBAMAZEPINE AND SERUM LIPID LEVELS
The effects of carbamazepine on serum lipid levels in 36 previously untreated patients with recently diagnosed idiopathic epilepsy were evaluated in a 1 to 5-year follow-up study at the Departments of Neurology and Clinical Chemistry, University of Oulu, Finland. Serum cholesterol, high-density lipoprotein (HDL) cholesterol, and g-glutamyltransferase (GGT) levels increased after 2 months' carbamazepine treatment and remained high after 1 and 5 years follow-up. Cholesterol/HDL cholesterol ratios remained unchanged.
Serum low-density lipoprotein (LDL) cholesterol and triglycerides (TG) increased during the first year but were normal after 5 years on medication. The change in lipid metabolism may be associated with induction of liver enzymes during carbamazepine treatment for epilepsy, and may also have clinical relevance to the increased incidence of atherosclerosis and coronary heart disease in patients with epilepsy. ( COMMENT. A high index of suspicion for JME is indicated in young patients with early-morning seizures, especially those poorly controlled
